NANOVIRICIDES INC (NNVC) Stock Price, Quote, News and Overview
NYSEARCA:NNVC - American Stock Exchange - US6300873022 - Common Stock - Currency: USD
NNVC Quote, Performance and Key Statistics
NANOVIRICIDES INC
NYSEARCA:NNVC (2/5/2025, 8:17:14 PM)
After market: 1.28 -0.02 (-1.54%)1.3
+0.16 (+14.04%)
The current stock price of NNVC is 1.3 USD. In the past month the price decreased by -19.25%. In the past year, price increased by 14.04%.
NNVC Latest News, Press Releases and Analysis
NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025
NanoViricides Engages CRO for Phase II Clinical Trial
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
NNVC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.95 | 338.85B | ||
| AMGN | AMGEN INC | 15.53 | 165.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 957.73 | 125.79B | ||
| GILD | GILEAD SCIENCES INC | 22.49 | 124.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.7 | 78.76B | ||
| ARGX | ARGENX SE - ADR | N/A | 40.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.64B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.34B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.26B | ||
| NTRA | NATERA INC | N/A | 23.37B | ||
| BIIB | BIOGEN INC | 8.91 | 21.21B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.55 | 15.81B |
Related stock screener links
About NNVC
Company Profile
NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 7 full-time employees. The company went IPO on 2004-08-12. Its nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that it plans to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. The company is focused on advancing NV-387 into Phase II human clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 (API NV-387) is its nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is its other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
Company Info
NANOVIRICIDES INC
1 Controls Drive
Shelton CONNECTICUT 06484 US
CEO: Anil Diwan
Employees: 7
Company Website: http://www.nanoviricides.com/
Investor Relations: http://www.nanoviricides.com/investorinfo.html
Phone: 12039376137
NNVC FAQ
What is the stock price of NNVC?
The current stock price of NNVC is 1.3 USD.
What is the symbol for NANOVIRICIDES INC stock?
The exchange symbol of NANOVIRICIDES INC is NNVC and it is listed on the American Stock Exchange exchange.
On which exchange is NNVC stock listed?
NNVC stock is listed on the American Stock Exchange exchange.
Is NNVC a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for NNVC, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of NNVC.
Does NNVC stock pay dividends?
NNVC does not pay a dividend.
When does NNVC stock report earnings?
NNVC will report earnings on 2025-02-12.
What is the Price/Earnings (PE) ratio of NNVC?
NNVC does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.76).
What is the Short Interest ratio of NNVC stock?
The outstanding short interest for NNVC is 1.33% of its float.
NNVC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NNVC. When comparing the yearly performance of all stocks, NNVC turns out to be only a medium performer in the overall market: it outperformed 50.32% of all stocks.
NNVC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NNVC. NNVC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
NNVC Financial Highlights
Over the last trailing twelve months NNVC reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS decreased by 2.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -80.51% | ||
| ROE | -93.51% | ||
| Debt/Equity | 0 |
NNVC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to NNVC. The Buy consensus is the average rating of analysts ratings from 7 analysts.